Inhaled insulin getting close look by FDA

09/8/2005 | Reuters

The FDA has asked an advisory panel to consider if an inhaled insulin powder developed by Pfizer, Sanofi-Aventis and Nektar Therapuetics could have adverse effects on the lungs or blood sugar levels. The panel is scheduled to review Exubera today, and some analysts project the product, if approved, could generate sales of up to $2 billion a year.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Biostatistics
Edwards Lifesciences
Irvine, CA
Diagnostic Technician
Roche
Marlborough, MA
Test Technician
Roche
Marlborough, MA
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Senior Paralegal - Research & Development, and Medical
Boehringer Ingelheim
Ridgefield, CT